BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, recently published Q1 2023 financial results and provided a business update. “The Q1 2023 results were in line with analysts’ expectations. R&D expenses increased about $800,000 from Q1 2022, which BiondVax attributed to the initiation and ramp-up of R&D activities for its innovative nanosized VHH antibody (‘NanoAb’) platform. In particular, the company finalized a preclinical proof-of-concept study of its inhaled anti-COVID NanoAb drug, reporting in January that the therapy virtually eliminated the SARS-CoV-2 virus in the lungs of infected hamsters and virtually prevented illness when inhaled prophylactically. These results built on previously announced data indicating the NanoAb treatment led to significantly milder illness and faster recovery among hamsters in the experimental group compared with the control group. Bullish about BiondVax, the analysts at Aegis Capital Corp. continue to recommend shares of the company with a Buy rating and a $70 target price,” a recent article reads. “BiondVax boasts unique big pharma competencies, positioning it to bring innovative therapies to market quicker and at lower cost compared to other companies of similar size.”
To view the full article, visit https://ibn.fm/ys9SZ
About BiondVax Pharmaceuticals Ltd.
BiondVax is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. Since its inception, BiondVax has executed eight clinical trials including a seven-country, 12,400-participant phase 3 trial of its prior vaccine candidate and has built a state-of-the-art manufacturing facility for biopharmaceutical products. With highly experienced pharmaceutical industry leadership, BiondVax is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized antibody (“NanoAb”) pipeline. For more information, visit the company’s website at www.BiondVax.com.
NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork